Figure 4. Glycolysis potentiates STING-dependent DC antitumor function.

(A and B) ELISA analysis of BMDCs treated with 2-DG (1 mM; A) or DCA (10 mM; B) overnight and then stimulated with cGAMP for 8 hours. (C) MC38 tumor growth of WT mice transferred with cGAMP-stimulated BMDCs. BMDCs were labeled with CTV following 2-DG (1 mM) treatment for 8 hours. 2-DG–pretreated BMDCs were then stimulated with cGAMP for 4 hours. MC38 tumor-bearing WT mice were injected s.c. adjacent to the tumor with 2 × 10⁶ cGAMP-stimulated DCs on days 3 and 6 after tumor injection (n = 8). (D) The numbers of CTV⁺ DCs in the draining lymph nodes and tumors from mice from C on day 8 after tumor inoculation (n = 4). (E) The numbers of tumor-infiltrating CD4⁺ and CD8⁺ T cells from mice from C on day 14 after tumor inoculation (n = 4). (F and G) Flow cytometry analysis of tumor-infiltrating CD4⁺ and CD8⁺ T cells (F) or F4/80⁺ macrophages (G) from mice from C on day 14 after tumor inoculation. (H) Tumor growth of MC38 tumor-bearing WT mice transferred with cGAMP-stimulated DCs. BMDCs were pretreated with DCA (10 mM) for 8 hours and then stimulated with cGAMP for 4 hours. MC38 tumor-bearing WT mice were injected s.c. adjacent to the tumor with 2 × 10⁶ cGAMP-stimulated DCs on days 3 and 6 after tumor injection (n = 8). (I and J) Flow cytometry analysis of tumor-infiltrating CD8⁺ and CD4⁺ T cells of the mice from H. Representative data are shown from 2 (C–J) and 3 (A and B) independent experiments. Data are shown as the mean ± SEM. Statistical analysis was performed using 1-way ANOVA (A, B, D–G, and J) and 2-way ANOVA (C and H); *P < 0.05; **P < 0.01.